TRIMming p53's anticancer activity

S Elabd; G Meroni; C Blattner

doi:10.1038/onc.2016.33

TRIMming p53's anticancer activity

Oncogene. 2016 Oct 27;35(43):5577-5584. doi: 10.1038/onc.2016.33. Epub 2016 Feb 22.

Authors

S Elabd^{1

2}, G Meroni³, C Blattner¹

Affiliations

¹ Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Karlsruhe, Germany.
² Human Physiology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
³ Department of Life Sciences, University of Trieste, Trieste, Italy.

PMID: 26898759
DOI: 10.1038/onc.2016.33

Abstract

Several TRIM proteins control abundance and activity of p53. Along this route, TRIM proteins have a serious impact on carcinogenesis and prognosis for cancer patients. In the past years, a significant increase has been made in our understanding of how the TRIM protein family controls p53 activity.

Publication types

Review

MeSH terms

Adaptor Proteins, Signal Transducing / genetics
Adaptor Proteins, Signal Transducing / metabolism*
Animals
DNA Damage
Gene Expression Regulation, Neoplastic
Humans
Membrane Proteins / genetics
Membrane Proteins / metabolism*
Multigene Family
Neoplasms / genetics
Neoplasms / metabolism*
Neoplasms / pathology
Promyelocytic Leukemia Protein / genetics
Promyelocytic Leukemia Protein / metabolism
Protein Binding
Proto-Oncogene Proteins c-mdm2 / genetics
Proto-Oncogene Proteins c-mdm2 / metabolism
Tumor Suppressor Protein p53 / genetics
Tumor Suppressor Protein p53 / metabolism*

Substances

Adaptor Proteins, Signal Transducing
Membrane Proteins
Promyelocytic Leukemia Protein
TRAT1 protein, human
Tumor Suppressor Protein p53
Proto-Oncogene Proteins c-mdm2